Krystal Biotech raises $160M via PIPE on heels of FDA approval for gene therapy
Krystal Biotech has received $160 million in private financing days after the FDA approved Vyjuvek, a gene therapy for children with a rare skin disease called dystrophic epidermolysis bullosa, and Krystal’s first-ever approved treatment.
On Monday, the company announced it is selling more than 1.7 million shares at $92.50 a pop, a slight decline over Friday’s closing price of $96.06 a share. Avoro Capital Advisors and Redmile Group led the financing, with Braidwell LP and Frazier Life Sciences also pitching in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.